Streetbeat News

Stock Prices

AEM

Agnico Eagle Mines (NYSE:AEM) is scheduled to release its quarterly earnings report on February 15, 2024, with analysts expecting an EPS of $0.47. The company's past earnings performance shows a mix of misses and beats, with the share price reacting accordingly. Shares are currently trading at $44.98, down 8.52% over the last year. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 2:01 pm

CVE

Cenovus Energy (NYSE:CVE) is scheduled to release its quarterly earnings report on February 15, 2024, with analysts predicting an EPS of $0.25. The company's past earnings performance shows a mixed impact on its stock price, with the last quarter's EPS beat leading to a 2.0% drop in share price. Shares are currently trading at $16.22, down 11.7% over the last year. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 2:01 pm

AMAT

Applied Materials (AMAT) is scheduled to release its quarterly earnings report on February 15, 2024. Analysts predict an EPS of $1.91. The company's past performance shows a mix of earnings beats and misses, with stock price reactions varying accordingly. Shares have risen 58.42% over the last year, indicating a positive outlook from long-term investors. The focus will be on whether AMAT beats the EPS estimate and provides optimistic future guidance.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 2:01 pm

IINN

Inspira Technologies (IINN) stock surged 113.5% to $2.05 after announcing the U.S. Patent approval for its VORTX technology, a key component of the INSPIRA ART500 device. This innovation aims to revolutionize blood oxygenation by eliminating the need for fiber membranes, reducing blood cell damage. CEO Dagi Ben-Noon highlighted this as a critical advancement in patient care and healthcare technology.

Portfolio Pulse from Henry Khederian

February 14, 2024 | 2:01 pm

DE

Deere (NYSE:DE) is scheduled to release its quarterly earnings report on February 15, 2024, with analysts expecting an EPS of $5.19. Investors are hopeful for a beat on this estimate and positive guidance for future growth. Despite beating EPS estimates in the past four quarters, Deere's stock price has shown mixed reactions, with a general 5.07% decline over the last 52 weeks. The upcoming earnings report is crucial for investors, especially considering the stock's recent performance.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 2:01 pm

DKNG

DraftKings (NASDAQ:DKNG) is anticipated to report an EPS of $0.08 in its upcoming quarterly earnings on February 15, 2024. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for future growth. DraftKings has a history of beating EPS estimates, leading to significant share price increases. The stock has seen a 142.34% rise over the last 52 weeks, trading at $42.69 as of February 13.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 2:01 pm

LNT

Alliant Energy (NASDAQ:LNT) is scheduled to release its quarterly earnings report on February 15, 2024. Analysts predict an EPS of $0.55. The company's past performance shows a mix of earnings beats and misses, with the share price reacting accordingly. Shares are currently trading at $47.57, down 10.48% over the last year. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 2:00 pm

GS

NUKK

Nukkleus Inc. (NASDAQ:NUKK) shares fell in premarket trading after a significant rise the previous day. The drop follows the announcement of a term sheet for acquiring Mercury Global, a cross-border payments firm. Additionally, Goldman Sachs Group, Inc. (NYSE:GS) holds a 7.2% passive stake in Nukkleus. Nukkleus also announced an MOU to increase its stake in Jacobi Asset Management and a payments partnership in Africa, potentially raising its ownership in Jacobi to about 20%.

Portfolio Pulse from Nabaparna Bhattacharya

February 14, 2024 | 2:00 pm

RPRX

Royalty Pharma (NASDAQ:RPRX) is scheduled to release its quarterly earnings report on February 15, 2024, with an estimated EPS of $0.99. Investors are looking for an earnings beat and positive guidance for the next quarter. The company's past earnings performance shows a mix of beats and misses, with minor share price movements following the announcements. Currently, shares are trading at $29.31, down 21.29% over the last 52 weeks, indicating a bearish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 2:00 pm

ELV

Elevance Health (NYSE:ELV) has received 7 analyst ratings in the last three months, all somewhat bullish, with a recent shift in sentiment and price targets. The average 12-month price target is now $556.29, down from $562.67. Elevance Health, a leading U.S. health insurer and the largest provider of Blue Cross Blue Shield branded coverage, faces revenue challenges with a -0.47% decline but shows strong profitability and financial health indicators.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 2:00 pm